Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.

A number of other equities research analysts have also recently issued reports on FOLD. Cowen restated a “buy” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. Robert W. Baird restated an “outperform” rating and issued a $18.00 price objective (up from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Chardan Capital restated a “buy” rating and issued a $18.50 price objective (up from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Leerink Swann restated a “buy” rating and issued a $20.00 price objective (up from $17.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $18.31.

Amicus Therapeutics (NASDAQ:FOLD) traded down $0.15 during midday trading on Monday, hitting $15.72. The stock had a trading volume of 2,820,400 shares, compared to its average volume of 2,290,000. Amicus Therapeutics has a 12 month low of $5.07 and a 12 month high of $16.60. The company has a market cap of $2,610.00, a PE ratio of -8.59 and a beta of 1.72. The company has a quick ratio of 6.22, a current ratio of 6.32 and a debt-to-equity ratio of 0.39.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The firm had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. During the same quarter in the prior year, the firm posted ($0.33) earnings per share. The company’s revenue was up 419.0% on a year-over-year basis. equities research analysts forecast that Amicus Therapeutics will post -1.52 earnings per share for the current fiscal year.

In other Amicus Therapeutics news, SVP Daphne Quimi sold 8,000 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $14.72, for a total transaction of $117,760.00. Following the completion of the transaction, the senior vice president now owns 62,676 shares of the company’s stock, valued at approximately $922,590.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Donald J. Hayden, Jr. sold 20,000 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.00, for a total value of $300,000.00. Following the transaction, the director now directly owns 25,814 shares of the company’s stock, valued at approximately $387,210. The disclosure for this sale can be found here. Insiders have sold a total of 269,625 shares of company stock valued at $3,825,272 in the last ninety days. Insiders own 3.40% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Alliancebernstein L.P. grew its holdings in Amicus Therapeutics by 16.3% during the 2nd quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock valued at $2,073,000 after buying an additional 28,800 shares in the last quarter. Bank of Nova Scotia purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $1,944,000. American International Group Inc. grew its holdings in Amicus Therapeutics by 23.1% during the 3rd quarter. American International Group Inc. now owns 109,628 shares of the biopharmaceutical company’s stock valued at $1,653,000 after buying an additional 20,597 shares in the last quarter. Redmile Group LLC grew its holdings in Amicus Therapeutics by 5.9% during the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after buying an additional 668,080 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Amicus Therapeutics by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after buying an additional 430,486 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Amicus Therapeutics (FOLD) Rating Increased to Buy at BidaskClub” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/15/amicus-therapeutics-fold-rating-increased-to-buy-at-bidaskclub.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.